Crystal Structures of Phosphodiesterases 4 and 5 in Complex with Inhibitor 3-Isobutyl-1-methylxanthine Suggest a Conformation Determinant of Inhibitor Selectivity*

Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes controlling cellular concentrations of the second messengers cAMP and cGMP. Crystal structures of the catalytic domains of cGMP-specific PDE5A1 and cAMP-specific PDE4D2 in complex with the nonselective inhibitor 3-isobutyl-1-methylxanthine have been determined at medium resolution. The catalytic domain of PDE5A1 has the same topological folding as that of PDE4D2, but three regions show different tertiary structures, including residues 79-113, 208-224 (H-loop), and 341-364 (M-loop) in PDE4D2 or 535-566, 661-676, and 787-812 in PDE5A1, respectively. Because H- and M-loops are involved in binding of the selective inhibitors, the different conformations of the loops, thus the distinct shapes of the active sites, will be a determinant of inhibitor selectivity in PDEs. IBMX binds to a subpocket that comprises key residues Ile-336, Phe-340, Gln-369, and Phe-372 of PDE4D2 or Val-782, Phe-786, Gln-817, and Phe-820 of PDE5A1. This subpocket may be a common site for binding nonselective inhibitors of PDEs.

[1]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[2]  E. Degerman,et al.  Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). , 1995, Cellular signalling.

[3]  J. Corbin,et al.  9 – Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE5 , 1996 .

[4]  E. Degerman,et al.  cGMP-inhibited phosphodiesterases (PDE3 gene family). , 1996, Biochemical Society transactions.

[5]  Jorge Navaza,et al.  [33] AMoRe: An automated molecular replacement program package. , 1997, Methods in enzymology.

[6]  Weng-Lang Yang,et al.  Reinventing the Wheel of Cyclic AMP , 2002 .

[7]  J. Corbin,et al.  Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.

[8]  J. Corbin,et al.  Histidine-607 and histidine-643 provide important interactions for metal support of catalysis in phosphodiesterase-5. , 2000, Biochemistry.

[9]  J. Corbin,et al.  Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. , 1994, The Journal of biological chemistry.

[10]  S. Waldman,et al.  Guanylyl cyclases and signaling by cyclic GMP. , 2000, Pharmacological reviews.

[11]  Raymond Greene,et al.  Trends in Endocrinology , 1969 .

[12]  Jin Hwan Kim,et al.  Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules , 2003, Nature.

[13]  Joseph Markowitz,et al.  Crystal structure of phosphodiesterase 4D and inhibitor complex1 , 2002, FEBS letters.

[14]  M. Giovannoni,et al.  Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. , 2000, European journal of medicinal chemistry.

[15]  Hwa-Young Kim,et al.  Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. , 2003, Structure.

[16]  M. Movsesian Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure , 2000, Expert opinion on investigational drugs.

[17]  J. Beavo,et al.  Effects of xanthine derivatives on lipolysis and on adenosine 3',5'-monophosphate phosphodiesterase activity. , 1970, Molecular pharmacology.

[18]  D. Underwood,et al.  New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. , 2000, Current opinion in pulmonary medicine.

[19]  D. Pelligrino,et al.  Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation , 1998, Progress in Neurobiology.

[20]  M. Fitzgerald,et al.  Phosphodiesterase 4 inhibitors for the treatment of COPD. , 2002, Chest.

[21]  G. Livera,et al.  Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling* , 2003, The Journal of Biological Chemistry.

[22]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[23]  J. Huidobro-Toro,et al.  Molecular mechanism of cGMP‐mediated smooth muscle relaxation , 2000, Journal of cellular physiology.

[24]  M. Houslay,et al.  The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. , 1998, Advances in pharmacology.

[25]  T. Torphy Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[26]  David P. Rotella,et al.  INHIBITORS: CURRENT STATUS AND POTENTIAL APPLICATIONS , 2002 .

[27]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[28]  M. Houslay,et al.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. , 2003, The Biochemical journal.

[29]  C. Klein Nitric oxide and the other cyclic nucleotide. , 2002, Cellular signalling.

[30]  J. Fozard,et al.  Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. , 1996, TIPS - Trends in Pharmacological Sciences.

[31]  E. Degerman,et al.  Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. , 1995, Archives of biochemistry and biophysics.

[32]  C. Stief,et al.  Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: From bench to bedside , 2001, World Journal of Urology.

[33]  A. Robichaud,et al.  The next generation of PDE4 inhibitors. , 2001, Current opinion in chemical biology.

[34]  Y. Zhao,et al.  Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. , 2000, Science.

[35]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[36]  M. Conti,et al.  11 – An Isoform-selective Inhibitor of Cyclic AMP-Specific Phosphodiesterase (PDE4) with Anti-inflammatory Properties , 1996 .

[37]  J. Corbin,et al.  PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS , 2002, International journal of clinical practice.

[38]  J. Beavo,et al.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. , 2000, Current opinion in cell biology.

[39]  F. Antoni Molecular Diversity of Cyclic AMP Signalling , 2000, Frontiers in Neuroendocrinology.

[40]  C. Sargent,et al.  Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. , 2000, Immunopharmacology.

[41]  Yongge Liu,et al.  Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. , 2006, Cardiovascular drug reviews.

[42]  S. Jin,et al.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling , 2002, Trends in Endocrinology & Metabolism.